Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2alpha overexpression. - Wikidata - awgldk - TriplyDB

Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2alpha overexpression.

Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2alpha overexpression.

http://www.wikidata.org/entity/Q37330687

about

CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma.MicroRNAs in the Myocyte Enhancer Factor 2 (MEF2)-regulated Gtl2-Dio3 Noncoding RNA Locus Promote Cardiomyocyte Proliferation by Targeting the Transcriptional Coactivator Cited2.Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2α gene is associated with cisplatin resistance.The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways Activator protein-2α functions as a master regulator of multiple transcription factors in the mouse liver Aberrant expressions of AP-2α splice variants in pancreatic cancer The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.RGD Peptides-Conjugated Pluronic Triblock Copolymers Encapsulated with AP-2α Expression Plasmid for Targeting Gastric Cancer Therapy in Vitro and in Vivo.DKK3 blocked translocation of β-catenin/EMT induced by hypoxia and improved gemcitabine therapeutic effect in pancreatic cancer Bxpc-3 cell.MiR-193a-5p Targets the Coding Region of AP-2α mRNA and Induces Cisplatin Resistance in Bladder Cancers Effect of Wasabi Component 6-(Methylsulfinyl)hexyl Isothiocyanate and Derivatives on Human Pancreatic Cancer Cells.The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.Mucins and pancreatic cancer.Ectopic expression of AP-2α transcription factor suppresses glioma progression.Changes in transcriptional factor binding capacity resulting from promoter region methylation induce aberrantly high GDNF expression in human glioma.Molecular predictors of gemcitabine response in pancreatic cancer.AP2α controls the dynamic balance between miR-126&126* and miR-221&222 during melanoma progression.Proteome-based biomarkers in pancreatic cancer.Functions of the AP-2α gene in activating apoptosis and inhibiting proliferation of gastric cancer cells both in vitro and in vivo.

P2860

Q30988544-34E99FBC-4B7E-485A-BE28-2CC04BBF4F83 Q33288820-6243A902-E963-4764-8D7A-7EB315206A8A Q33403498-39620E91-68D5-4A15-8C8C-2668D0410C6C Q34110688-3C581A71-F28B-4719-92AD-B58243260375 Q34185812-D499A77E-6A03-459E-BF95-34A4C43A2D5C Q34193484-0E8EB068-536E-44DA-B652-1A052EC95001 Q35049500-BEE03142-1F3B-4543-947A-F9444706DAED Q35793641-C0601375-E97A-44D4-826D-2552BA2018A1 Q35902627-14CCADC0-D9BD-493C-AA41-C5D6994804B1 Q36394714-4EF36DBF-1D67-4127-BF3E-BAA3D3BCB6F6 Q37290580-CA6A1091-87E1-497F-B788-27AD0C80AB9D Q37569815-512B0095-8990-4EBC-94B7-013DB7DB776B Q37605606-9261EA98-E2E6-4289-A0AA-C38F6292E654 Q38166583-5A9898BD-F267-4493-ABCF-1852362DB8C7 Q38910475-C2D3FF6E-104E-4838-95C5-3EA05BFBF9E7 Q39162671-6608522B-FF81-45A4-B2CA-71706448D90F Q39250668-42694FD4-2266-421A-8ACF-222C43BD1F8F Q42712113-DEEF73DA-6CCD-4BA2-912E-BD7AFE9A10EA Q43008803-365F48E3-3E2E-49D0-A431-FCC908170B3C Q45875109-2734D8C6-47BD-4F31-929B-AA433F1BF52F

P2860

Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2alpha overexpression.

http://www.wikidata.org/entity/Q37330687

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Tumour growth and resistance t ...... d by AP-2alpha overexpression.

@en

Tumour growth and resistance t ...... d by AP-2alpha overexpression.

@nl

type

label

Tumour growth and resistance t ...... d by AP-2alpha overexpression.

@en

Tumour growth and resistance t ...... d by AP-2alpha overexpression.

@nl

prefLabel

Tumour growth and resistance t ...... d by AP-2alpha overexpression.

@en

Tumour growth and resistance t ...... d by AP-2alpha overexpression.

@nl

P1433

Q37330687-10287FC4-4CDA-4764-89A7-D83AE531F763

P1476

Q37330687-A9819EC1-19F4-41B9-BAEF-A4EDF7124C9A

P2093

Q37330687-06AD2B9F-6E20-4C2A-BCF2-D0F85C0CADA3

Q37330687-0D21A87C-1447-45AA-BAFD-F0C23D2BDC8A

Q37330687-37F4BFED-30FB-4D06-B30D-05F9460DC9FE

Q37330687-507B2609-4E3D-43ED-9E99-9B87AABB2D2B

Q37330687-7B310D14-21DC-4938-84CB-9504C7D15BE1

Q37330687-8EA7BBD6-00E3-40FD-AA64-CFA4C2F7BA35

Q37330687-EFF838FD-6B94-4F5A-989D-2B7F75A25562

Q37330687-F17040E2-30EE-4CC7-ACC9-1B972219EFEA

P2860

Q37330687-06A19AD5-7D97-455E-8EDF-D9AFE1D58F09

Q37330687-09374642-FB60-47AD-BAD2-22EA65327B33

Q37330687-1EB4F81F-1957-4469-A189-10FB681F905E

Q37330687-25F5A63C-352B-4FB9-8846-0EA5D642C765

Q37330687-3937A2DF-1E2A-4B39-A81C-F2DD5E32D487

Q37330687-3C9F7C5F-0170-494C-875A-651ADB210F3E

Q37330687-5AD4F585-4DB7-4453-A62E-244EA14B21CF

Q37330687-5DE6B9CC-568A-479A-B5A3-8C95C61B0A22

Q37330687-89C0548B-19F9-4177-87E5-161A10C83EC0

Q37330687-9C1DD595-E7F3-48D5-A02B-0BD861901D57

P2888

Q37330687-4DB77AA8-EF86-4813-B8C7-1A27C0AD9253

P304

Q37330687-153C8A37-317E-4B3E-A58C-A45974FAE793

P31

Q37330687-C80A5A22-7120-429F-80A1-2A1DEDC699A4

P356

Q37330687-F0E85C1D-3D2C-4481-9722-328086D3B2FA

P407

Q37330687-41716658-31B3-489C-AFEF-C496C1938FD4

P433

Q37330687-FAF1ECD9-1486-4677-9763-03AEA7DFD7D5

P478

Q37330687-FA49A917-BA42-43DC-83A1-22E140B90771

P50

Q37330687-D66FF7DC-8128-4EFC-912D-211F9A5DB1D4

Q37330687-F5C26A49-1496-4E60-8211-C0B0760B01C3

P577

Q37330687-A5297177-71E3-4E9B-86E0-11FB8523102C

P5875

Q37330687-C8F02C86-A866-4608-BABA-3FE79F7E5885

P698

Q37330687-DCA55D9F-2AD3-4046-A643-7CB37065E5C8

P921

Q37330687-32CA2912-5B10-4207-8C87-A410FBF67C09

P932

Q37330687-6E151A26-E716-4481-8EC9-DCDB2D7344E2

P356

P1433

British Journal of Cancer

P1476

Tumour growth and resistance t ...... ed by AP-2alpha overexpression

@en

P2093

C Susini

http://www.w3.org/2001/XMLSchema#string

G Huet

http://www.w3.org/2001/XMLSchema#string

L Stechly

http://www.w3.org/2001/XMLSchema#string

N Porchet

http://www.w3.org/2001/XMLSchema#string

N Saint-Laurent

http://www.w3.org/2001/XMLSchema#string

P Pigny

http://www.w3.org/2001/XMLSchema#string

S Aubert

http://www.w3.org/2001/XMLSchema#string

V Fauquette

http://www.w3.org/2001/XMLSchema#string

P2860

The AP-2 family of transcription factors

Cell cycle, CDKs and cancer: a changing paradigm

The antagonistic regulation of human MUC4 and ErbB-2 genes by the Ets protein PEA3 in pancreatic cancer cells: implications for the proliferation/differentiation balance in the cells

MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells

Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors.

Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27(kip), but does not activate mitogen-activated kinase or protein kinaseB/Akt pathways.

Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents.

Loss of AP-2alpha results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo.

AP-2alpha and AP-2gamma regulate tumor progression via specific genetic programs.

Pancreatic cancer: basic and clinical aspects.

P2888

P304

637-644

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605190

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

Nicolas Jonckheere

Isabelle Van Seuningen

P577

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26733771

http://www.w3.org/2001/XMLSchema#string

P698

19672266

http://www.w3.org/2001/XMLSchema#string

P921

P932

2736821

http://www.w3.org/2001/XMLSchema#string